266 filings
Page 10 of 14
424B5
zq8v99a632f918191mbd
30 Mar 20
Prospectus supplement for primary offering
8:39am
8-K
getexja 22goqjkbd
30 Mar 20
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
8:32am
8-K
zqu0nhlqq4fw
18 Mar 20
Other Events
8:04am
8-K
osopr sbf
17 Mar 20
Other Events
8:23am
4
ovvu8kf07
16 Mar 20
Eton Pharmaceuticals / MARK L BAUM ownership change
4:58pm
4
emw5zc vs
16 Mar 20
Eton Pharmaceuticals / William Wilson Troutman ownership change
4:56pm
4
clle6
16 Mar 20
Eton Pharmaceuticals / CHARLES J CASAMENTO ownership change
4:56pm
4
levlvwonk9q4x
16 Mar 20
Eton Pharmaceuticals / PAUL V MAIER ownership change
4:54pm
4
1uya4gnun2re f6gswy
16 Mar 20
Eton Pharmaceuticals / NORBERT G RIEDEL ownership change
4:52pm
4
j9u2o00
16 Mar 20
Eton Pharmaceuticals / SEAN BRYNJELSEN ownership change
4:52pm
8-K
yaxbsr
6 Mar 20
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
7:37am
8-K
952 1ixec1d
19 Feb 20
Eton Pharmaceuticals Provides Update on ET-105 Program
8:30am
SC 13G/A
fn20sh34h9vvq4ty7p44
14 Feb 20
Beneficial ownership report (amended)
12:00am
SC 13G/A
zksx ikdlioaqrmk8b
4 Feb 20
Beneficial ownership report (amended)
4:51pm
8-K
q4bgm2ffeyz1h4dxics
21 Jan 20
Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement
7:52am
EFFECT
9eujt7
17 Dec 19
Notice of effectiveness
12:15am
8-K
isluz
12 Dec 19
Other Events
7:41am
CORRESP
9hcea83hphov9t
12 Dec 19
Correspondence with SEC
12:00am
UPLOAD
m0wu3hf26onwuwpdxr
10 Dec 19
Letter from SEC
12:00am